Document is current
Any future updates will be listed below
-
Authors
Oliai, Caspian
Douek, Michael L.
Rhoane, Caelainn
Bhutada, Abhishek
Ge, Phillip S.
Runyon, Bruce A.
Wang, Xiaoyan
Hurvitz, Sara A. https://orcid.org/0000-0001-7808-7191
-
Funding
Funding for this research was provided by:
National Cancer Institute (CA016042)
- License Information
-
More Information
Article History
Received: 28 May 2019
Accepted: 31 May 2019
First Online: 7 June 2019
Compliance with ethical standards
:
: SH receives research funding paid to UCLA by Ambrx, Amgen, Bayer, Boehringer Ingelheim, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Macrogenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, PUMA, Roche, and Seattle Genetics. SH has had travel support from Lilly, Novartis, and OBI Pharma. The other authors declare that they have no conflicts of interest.
: This retrospective analysis was approved by the Institutional Review Board of the University of California, Los Angeles, which determined that informed consent was exempt for a retrospective study.
: This is a declaration that all aspects of this study comply with the current laws of the United States. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
